Tag: Eculizumab

Neurology

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

Newsemia
The terminal complement inhibitor eculizumab was shown to improve myasthenia gravis-related symptoms in the 26-week, phase 3, randomized, double-blind, placebo-controlled REGAIN study (NCT01997229). In this...
Latest News

Atypical haemolytic uraemic syndrome in the eculizumab era: presentation, response to treatment and evaluation of an eculizumab withdrawal strategy

Newsemia
Neave, L; Gale, DP; Cheesman, S; Shah, R; Scully, M; (2019) Atypical haemolytic uraemic syndrome in the eculizumab era: presentation, response to treatment and evaluation...
Neurology

PREVENT: Eculizumab May Lower Relapse Risk in NMOSD

Newsemia
Use of eculizumab resulted in significantly greater relapse reduction over placebo in patients with neuromyelitis optica spectrum disorder (NMSOD), new findings from the phase 3...
Latest News

Drug reduces risk of relapse with neuromyelitis optica spectrum disorder, study shows

Newsemia
The drug eculizumab, a synthetic antibody that inhibits the inflammatory response, significantly reduced the risk of relapse with neuromyelitis optica spectrum disorder. Source link...
Neurology

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

Newsemia
Alexion Pharmaceuticals, Inc. today announced positive topline results from the Phase 3 PREVENT study of Soliris in patients with anti-aquaporin-4 auto antibody-positive neuromyelitis optica spectrum...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy